Hizentra 10 g Human Normal Immunoglobulin 20%

Description

Hizentra 10 g is a 20% human normal immunoglobulin (200 mg/mL) solution for subcutaneous infusion. The 10 g presentation contains 50 mL and is used under specialist supervision to provide immunoglobulin replacement or approved maintenance therapy. This page explains its approved uses, practical administration, important warnings, monitoring and verified storage conditions.

What is Hizentra 10 g?

Hizentra contains human normal immunoglobulin, a purified preparation of IgG antibodies obtained from human plasma. These antibodies support immune defence when the body cannot make enough effective antibodies. It is supplied as a ready-to-use 20% solution for administration into the tissue under the skin. It must never be injected into a blood vessel.

Hizentra is a prescription medicine. Selection of the indication, dose, infusion frequency, infusion sites and monitoring plan must be made by an immunology or neurology specialist. The pack strength alone does not determine a patient’s dose.

3 approved uses of Hizentra

1. Primary immunodeficiency syndromes: replacement therapy for people whose immune system does not produce adequate antibodies.
2. Secondary immunodeficiency: replacement therapy in selected patients with severe or recurrent infections when antimicrobial treatment has been ineffective and there is proven antibody failure or a very low serum IgG level.
3. Chronic inflammatory demyelinating polyneuropathy (CIDP): maintenance treatment after the patient has been stabilised with intravenous immunoglobulin. CIDP is a neurological condition affecting peripheral nerves and requires specialist diagnosis and follow-up.

The approved indication can vary by country and the exact product information supplied with the medicine should always be followed. The European Medicines Agency provides the current regulatory overview for Hizentra.

How Hizentra works

The medicine supplies a broad range of human IgG antibodies. In immunodeficiency, these antibodies help replace missing immune protection and reduce susceptibility to serious or repeated infections. In CIDP maintenance, immunoglobulin has immune-modulating effects that can help preserve the response achieved with intravenous immunoglobulin. It does not cure the underlying condition, and ongoing assessment is necessary to confirm benefit and safety.

Subcutaneous infusion and home use

Hizentra is infused under the skin using appropriate infusion equipment. Common sites may include the abdomen, thigh, upper arm or hip, depending on the clinical plan and the authorised instructions. More than one site may be used when clinically appropriate. The solution should be inspected before use and should not be used if it is cloudy, contains particles, has been frozen or the container is damaged.

Home administration may be possible only after the patient or caregiver has received adequate training. Training should cover aseptic technique, preparation, infusion equipment, site rotation, treatment records, recognition of adverse reactions and what to do in an emergency. A trained patient must still remain under regular medical supervision.

Do not copy another patient’s dose or infusion schedule. The specialist adjusts treatment according to body weight, diagnosis, previous immunoglobulin therapy, clinical response, infection history, IgG trough levels where relevant and tolerability.

Monitoring before and during treatment

• Review previous reactions to immunoglobulins and any known allergy to blood-derived products.
• Check hydration status and relevant kidney, blood and clotting risk factors when clinically indicated.
• Monitor clinical response, infection frequency, neurological function in CIDP and laboratory results requested by the treating team.
• Observe carefully when starting treatment, changing product, resuming after a long interruption or increasing the infusion rate.
• Record the product name and batch number to maintain traceability.

Important warnings and contraindications

Hizentra must not be used in people with hyperprolinaemia. It must not be administered intravascularly because accidental injection into a blood vessel can cause a serious reaction. Tell the specialist about IgA deficiency, previous severe allergy, heart or vascular disease, clotting history, prolonged immobility, kidney disease, diabetes, dehydration, anaemia, pregnancy, breastfeeding and all current medicines.

Stop the infusion and seek urgent medical help for breathing difficulty, swelling of the face or throat, widespread hives, faintness, severe chest pain, sudden weakness, a painful swollen limb, severe persistent headache with neck stiffness, dark urine or any rapidly worsening reaction. Severe allergy or anaphylaxis is uncommon but can occur, including in someone who previously tolerated immunoglobulin.

Immunoglobulin products are manufactured with multiple safety steps, yet a theoretical risk associated with medicines made from human plasma cannot be completely excluded. This is another reason to keep the batch details and use the product only through an authorised supply chain.

Possible side effects

Frequently reported effects include local infusion-site swelling, redness, pain, itching or bruising. Headache, rash, muscle or joint pain, fatigue and flu-like symptoms may also occur. Reactions can be more noticeable during the first treatments or after a treatment gap. The treating team may adjust the technique, site, volume or rate when medically appropriate.

Less common but potentially serious effects include severe hypersensitivity, thromboembolic events, aseptic meningitis syndrome, haemolysis and other blood abnormalities. Any unusual or persistent symptom should be reported promptly rather than managed by changing the prescribed regimen without advice.

Vaccines and other medicines

Human immunoglobulin may reduce the effectiveness of some live attenuated vaccines for a period of time. Tell the vaccination provider when Hizentra was last given so the correct interval can be determined. Give the specialist a complete list of prescription medicines, non-prescription products, supplements and recent vaccines.

Verified storage for Hizentra 10 g

Store Hizentra below 25°C, do not freeze it, and keep it in the outer carton to protect it from light. Use the product immediately after opening and do not use it after the expiry date. Keep it out of the sight and reach of children. Do not dispose of unused medicine in household wastewater; ask a pharmacist about safe disposal. The current Summary of Product Characteristics should be checked for full storage and handling instructions.

Buying Hizentra from No Style Like

No Style Like helps customers understand specialist medicines and product availability. Visit our English homepage or contact the support team before ordering to confirm availability, prescription requirements, shipping conditions and cold-chain or temperature-control arrangements where applicable. Availability information is not a substitute for a medical prescription or diagnosis.

Medical notice

This educational page does not replace the official patient leaflet, the prescribing information or advice from a qualified healthcare professional. Hizentra should be used only for an approved indication, with an individual treatment plan and ongoing specialist monitoring. Never start, stop, share or change immunoglobulin treatment without the treating physician.